CompletedNCT02935725
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
Medication studyAges 18–45United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- Autifony Therapeutics Limited
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT02935725
- Official title
Show the full official title
A Phase 1, Single-centre, Double-blind, Placebocontrolled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants
Get this study by email
Recruitment & locations
CompletedLondon
Questions about this study
Who is behind this study?
The study sponsor is Autifony Therapeutics Limited.
Did this study involve medication?
Yes. The study involved medication, including Low dose AUT00206 800mg, High dose AUT00206 2000 mg, Placebo and ketamine.
Who was this study for?
Listed age limits: 18 years to 45 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication